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Abstract
Systemically administered DNA encoding a recombinant human immunodeficiency virus (HIV) derived immunogen effectively primes
a cytotoxic T lymphocyte (CTL) response in macaques. In this further pilot study we have evaluated mucosal delivery of DNA as an
alternative priming strategy. Plasmid DNA, pTH.HW, encoding a multi-CTL epitope gene, was incorporated into poly(D,L-lactic-co-glycolic
acid) microparticles of less than 10 m in diameter. Five intrarectal immunizations failed to stimulate a circulating vaccine-specific CTL
response in 2 Mamu-A*01 rhesus macaques. However, 1 week after intradermal immunization with a cognate modified vaccinia virus
Ankara vaccine MVA.HW, CTL responses were detected in both animals that persisted until analysis postmortem, 12 weeks after the final
boost. In contrast, a weaker and less durable response was seen in an animal vaccinated with the MVA construct alone. Analysis of lymphoid
tissues revealed a disseminated CTL response in peripheral and regional lymph nodes but not the spleen of both mucosally primed animals.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The development of an effective acquired immunodefi-
ciency syndrome (AIDS) vaccine demands novel ap-
proaches as many of the more conventional vaccine modal-
ities have proven unsuitable when tested in the simian
immunodeficiency virus (SIV) primate model. The potent
protection elicited by live-attenuated SIV, that has been
shown to be durable, effective against high dose cell-free
challenge, against challenge with virus infected cells,
against challenge with heterologous virus, and against chal-
lenge via mucosal surfaces, is a paradigm for the develop-
ment of an effective AIDS vaccine (reviewed by Johnson
and Desrosiers, 1998). The correlates of protective immu-
nity are still incompletely understood in this system; how-
ever, generation of a SIV-specific cytotoxic T lymphocyte
(CTL) response is believed to be an important factor in
control of virus load (Jin et al., 1999; Schmitz et al., 1999)
and the level of CTL activity has been correlated with
protective efficacy after vaccination with live-attenuated
vaccine (Johnson et al., 1999) and following vaccination
with a recombinant vaccinia virus vector expressing SIV nef
(Gallimore et al., 1995). The ability of live viruses to stim-
ulate a widely disseminated specific immune response is
almost certainly a factor in their efficacy. It is likely that the
most effective AIDS vaccine will stimulate both local and
systemic immunity as is seen with live-attenuated SIV.
Replication of the live-attenuated vaccine in regional lym-
phoid tissue presumably accounts for the generation of local
immunity and persistence of the virus, albeit at extremely
low levels, at least as far as detection in the peripheral
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circulation is concerned, is thought to be a factor in the
longevity of the protective response generated. Unfortu-
nately, live-attenuated vaccines present an unacceptable
level of risk due to reversion to virulence (Whatmore et al.,
1995) and an incomplete knowledge of host and viral vir-
ulence factors (Baba et al., 1995). Thus alternative, safer
modalities that can stimulate qualitatively and quantitatively
similar responses to those generated by live-attenuated virus
are being sought.
DNA vaccination in some ways emulates infection with
a live-attenuated virus. Although DNA does not replicate, it
may persist for some time at the site of injection (Hanke et
al., 2002) and influence the dissemination and longevity of
the immune response generated. In human immunodefi-
ciency syndrome (HIV) and SIV infection the gut is a
principle portal of virus entry and regardless of route of
infection lymphoid tissue associated with the gut (GALT) is
a primary site of virus replication early after exposure (Vea-
sey et al., 1998; Canto-Nogues et al., 2001). It is therefore
logical to target GALT for the stimulation of protective
immune responses against HIV and SIV. There is at present
relatively little information about DNA immunization in the
gut. Direct administration of measles virus hemagglutinin
(HA)-encoding plasmid DNA to mucosal surfaces has been
shown to induce measles virus-specific CTL in mice; how-
ever, the oral route of administration was inefficient without
the use of mucosal adjuvants (Etchart et al., 1997). Micro-
particles composed of poly(D,L-lactic-co-glycolic acid)
(PLGA), which is biocompatible and has an extensive
record of safe use in humans, have been shown to efficiently
deliver protein antigens following gut administration elicit-
ing both systemic and mucosal immune responses (Eldridge
et al., 1991). This is believed to be due to the fact that
microparticles of less than 10 m are readily taken up by
macrophages and intestinal M cells leading to antigen pre-
sentation in regional inductive immune sites. More recently,
it was shown that PLGA-encapsulated plasmid DNA elicits
systemic and mucosal antibodies to the encoded antigen
after oral delivery in mice (Jones et al., 1997). In the human
rotavirus murine-challenge model protective immune re-
sponses have been generated after oral gavage with mi-
croencapsulated DNA encoding rotavirus VP6 (Chen et al.,
1998) and VP4 and VP7 (Hermann et al., 1999). Further-
more, the induction of systemic and local antibodies and
CTL responses has been demonstrated in mice immunized
orally with microparticles containing DNA encoding HIV
Env glycoprotein (Kaneko et al., 2000).
One particularly promising approach for the stimulation
of strong and durable CTL responses is the DNA prime–
viral vector boost regimen (reviewed by Seder and Hill,
2000). A synthetic multiepitope gene (Hanke et al., 1998)
encoding human immunodeficiency virus type 1 (HIV-1)
CTL epitopes and including the SIV Gag181–189 CTL
epitope that is restricted by the Mamu-A*01 rhesus ma-
caque major histocompatibility complex (MHC) class I
molecule (Miller et al., 1991; Allen et al., 1998) has been
shown to prime a CD8 CTL response in macaques follow-
ing intradermal administration with a gene gun. Circulating
CD8 CTL were demonstrated following boosting with
modified vaccinia virus Ankara (MVA) expressing the same
multiepitope gene (Hanke et al., 1999).
In the small-scale pilot study reported here, we have
extended the previous study to determine whether muco-
sally administered HIV multiepitope DNA induces directly
or primes a CTL response. PLGA microparticles containing
plasmid DNA were formulated using an optimized proce-
dure utilizing pharmaceutically approved reagents (Tinsley-
Bown et al., 2000). The particles were made to an optimal
size to facilitate their uptake by M cells of the gut and were
administered rectally.
Results and discussion
Three batches of microparticles containing the multie-
pitope plasmid DNA pTH.HW were made. Analysis of
DNA incorporation per milligram PLGA showed that 5.95
g of DNA was incorporated in batch 1, 8.5 g of DNA
was incorporated in batch 2, and 8.4 g of DNA was
incorporated in batch 3. In all batches, greater than 90% of
the particles were found to be less than 10 m in size with
an average size of 2.7 m and therefore of a size suitable for
uptake through M cells. The external structure of particles
was examined by electron microscopy and generally the
particles were found to be spherical with smooth surfaces.
Next, the physical state of the encapsulated DNA was ex-
amined following release into solution. Gel electrophoresis
revealed a high proportion of supercoiled form. Transfec-
tion of 293 cells with extracted DNA showed that biological
activity was present (data not shown). To determine if
microparticles could be phagocytosed and instigate expres-
sion of the encapsulated DNA within the cells, micropar-
ticles were added to monolayers of the mouse monocyte
macrophage cell line RAW 264.7. Following incubation for
72 h, expression of the HW immunogen was shown by
detection of the SV5 Pk tag epitope by immunofluorescent
staining with monoclonal antibody on fixed permeabilized
cells (Fig. 1). Expression was seen in the majority of cells
incubated with between 5 and 20 g of DNA.
To determine the immunogenicity of the microencapsu-
lated DNA, two rhesus macaques (Z14, Z55) positive for
the Mamu-A*01 MHC were immunized intrarectally with
microparticles (batch 1) containing 300 g pTH.HW at
weeks 0, 4, and 8. Significant lytic activity was not detected
at any effector-to-target ratio (E:T) in the range 6:1 to 200:1
in either animal in peptide-restimulated peripheral blood
mononuclear cells (PBMC) taken 3 weeks after the first
immunization, 3 weeks after the second immunization, or 3
weeks after the third immunization (Fig. 2). This result was
no different than that obtained in macaques vaccinated with
the same plasmid DNA construct administered intrader-
mally with the Dermal XR particle delivery device (Pow-
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derJect Vaccines Inc.) (Hanke et al., 1999). Oral adminis-
tration of the microparticles to BALB/c mice at a dose of
200 g also failed to stimulate significant CTL activity to
the H-2Dd-restricted HIV-1 epitope RGPGRAFVTI, en-
coded by the multiepitope construct, in splenocytes or in
mononuclear cells isolated from mesenteric lymph nodes 3
and 9 weeks after immunization (data not shown). To de-
termine if a higher dose of DNA would stimulate a directly
measurable systemic CTL response, animals Z14 and Z55
next received two further doses of 3 mg DNA in micropar-
ticles (a 50:50 mix of batches 2 and 3) at weeks 35 and 39.
Again no significant lytic activity was detected in peptide-
restimulated PBMC taken 2 weeks after each of these sub-
sequent immunizations. An equivalent dose could not be
tested in mice due to the limitation imposed by volume. To
determine if the macaques had been primed for a CTL
response, both animals were further immunized intrader-
mally, 9 weeks after the final DNA immunization, with the
cognate recombinant MVA.HW expressing the polyepitope
gene. A naive Mamu-A*01 macaque (445) was also sim-
ilarly immunized. On the day of immunization, lytic activity
was not detected in either the DNA vaccinated or the naive
animal (Fig. 2). When tested 1 week after immunization
with the MVA construct, all three animals revealed
Gag181–189-specific CTL activity in restimulated PBMC;
however, in the non-DNA immunized animal this response
was weak, only reaching above the 10% cut off at effector-
to-target ratios of 50:1 and greater and was only 14% above
cutoff at 200:1. Furthermore, 1 week later, lytic activity was
undetectable in this animal and remained undetectable sub-
sequently, 4, 6, and 8 weeks after MVA vaccination even at
an E:T of 200:1. In contrast, 1 week after MVA immuni-
zation, significant lytic activity of 16 and 21% was seen in
animals Z14 and Z55, respectively, even at the lowest E:T
tested of 6:1 rising to 28 and 43% at 200:1. Furthermore, the
responses were persistent (Fig. 2) with between 20 and 14%
lytic activity detected 4 weeks after MVA vaccination even
at 12.5:1 and up to 31% killing detected at higher E:T. To
determine if the responses could be further boosted, animals
were immunized again with MVA.HW. One week later, all
animals had higher levels of lytic activity. In 445, lytic
activity returned to a level greater than seen after the first
MVA immunization, although significant killing was unde-
tectable below an E:T of 25:1 and the response was not
durable. In contrast, Z14 and Z55 had persistent responses
(Fig. 2) and although these had declined somewhat by 12
weeks after the boost, killing was still detectable above the
cutoff at an E:T of 12.5:1.
The accelerated response in DNA-immunized macaques
following MVA immunization is similar to that reported
previously in macaques vaccinated using the gene-gun fol-
lowed by MVA (Hanke et al., 1999); indeed in that study,
only one of three macaques had lytic activity by 1 week
after the first MVA vaccination but all animals developed
CTL responses subsequently. Although only one Mamu-
A*01 macaque was available to us in this study as an
Fig. 1. RAW 264.7 cells phagocytose PLGA/pTH.HW microparticles and express the HW immunogen. Untreated cells (A) and cells exposed to
microencapsulated DNA (B) were fixed and permeabilized and recombinant protein was detected by staining with a monoclonal antibody with specificity
for the SV5 Pk epitope followed by FITC-conjugated anti-mouse lg goat F(ab’)2.
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MVA-alone control; the results from this animal were com-
pletely consistent with those obtained from the two MVA-
alone controls used in the previous study (Hanke et al.,
1999). In that study a single vaccination with MVA failed to
stimulate SIV Gag181–189-specific CD8 cells detectable
with MHC-peptide tetrameric complexes and even two im-
munizations induced only a slow and very weak response.
In the present study, lytic activity was detected after re-
Fig. 2. Longitudinal analysis of CTL activity in SIV Gag181–189 peptide-restimulated PBMC taken from vaccinated macaques. Macaques Z14 (A) and Z55
(B) were vaccinated first with 300 g three times followed by 3 mg doses given twice of plasmid DNA pTH.HW encapsulated in PLGA intrarectally.
Subsequently, Z14 and Z55 together with a non-DNA-primed macaque, 445 (C), received two intradermal immunizations with 5  108 PFU of MVA.HW
as indicated by the vertical divisions. Results are shown as net percentage specific lysis following subtraction of lysis obtained on peptide unpulsed autologous
B-LCL for an effector:target ratio of 100:1.
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stimulation but this was weak after a single immunization
and transient even after two immunizations. Taken together,
these results indicate that prior exposure to cognate DNA
primed the CTL response and that mucosal exposure to
DNA could effectively prime a circulating response.
Next the distribution of CTL activity was analyzed post-
mortem in a variety of lymphoid organs. CTL activity was
detected in iliac, inguinal, mesenteric, and axillary lymph
nodes but not in the spleen of both mucosally primed ani-
mals (Fig. 3). In the animal vaccinated with MVA without
DNA priming, a titratable CTL response was detected only
in cells from axillary lymph nodes at and above an E:T of
50:1 and killing reached a level of only 28% even at the
highest E:T of 200:1. Cells from all other tissues tested were
essentially unreactive, or had low levels of lytic activity that
did not titrate in a reproducible manner. Interestingly, both
animals that had been vaccinated first with DNA had strong
CTL memory responses in the interior iliac lymph nodes.
This is particularly encouraging since these nodes drain the
rectal–genital tract, are known to be an early site of virus
replication following mucosal challenge (Spira et al., 1996),
contain precursor CTL following infection of macaques
systemically with attenuated SIV (Cranage et al., 1997) and
immunization targeting these nodes has been associated
with protection from virus challenge (Lehner et al., 1996).
The failure to detect CTL activity in splenocytes was sur-
prising and may indicate that the response detected in
PBMC represents cells that are recirculating to local tissues
rather than resident in the secondary lymphoid compart-
ment. Lytic activity was not detected in direct, unstimulated
CTL assays using cells from any of the lymphoid tissues
including blood and intraepithelial lymphocytes recovered
from jejunum. Cells from jejunal lamina propria had poor
viability and bacterial contamination was shown to be
present. However, in macaque Z14 we were able to obtain
cells from tonsils and these revealed specific lytic activity
after restimulation, suggesting that the DNA-prime MVA
boost regimen may have stimulated a disseminated mucosal
immunity.
Further work is required to determine the optimal re-
quirements for mucosal priming with DNA. In this pilot
study, relatively large doses of DNA were administered and
it was not possible to define whether high and repeated
doses were necessary. It is unlikely that the current formu-
lation is optimal. While incorporation of the DNA into the
particle has the advantage of facilitating control of the
release profile, such encapsulation may also physically
damage the DNA. An alternative procedure has been de-
scribed recently where DNA adsorbed onto cationic PLGA
microparticles given parenterally to small animals and pri-
mates elicited enhanced HIV-specific immune responses
compared to those obtained after naked DNA immunization
(O’Hagan et al., 2001). Furthermore, in mice, enhanced
mucosal and systemic immunity was seen following intra-
nasal administration (Singh et al., 2002). For optimization
studies, it will be important to use quantitative assays such
as staining with tetrameric MHC–peptide complexes. A
faulty batch of tetramers precluded such analysis in the
present study.
Fig. 3. CTL activity in cells recovered from lymphoid compartments of
immunized macaques postmortem. Net percentage specific lysis is shown for
a range of effector:target using SIV Gag181–189 peptide-restimulated cells
recovered from (F) iliac, (E) inguinal, () mesenteric, and (ƒ) axillary lymph
nodes, () spleen, and () tonsil of macaques primed with pTH.HW DNA
and boosted with MVA.HW (A and B: macaques Z14 and Z55, respectively)
and an animal immunized only with MVA.HW (C: macaque 445).
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The mechanism by which microparticles deliver DNA is
poorly understood. Although microparticles may directly
facilitate the uptake of DNA into antigen-presenting cells
and may prolong gene expression (Singh et al., 2002), they
may also have an additional adjuvanting property since
empty particles coadministered with DNA into the perito-
neal cavity of mice have been shown to enhance the hu-
moral immune response to the encoded antigen (Fooks et
al., 2000). Clearly, further studies are required to establish,
in primates, whether the PLGA is essential for the priming
activity of the mucosally delivered DNA.
The rectum is an immune inductive site (Lehner et al.,
1994; Klavinskis et al., 1996); however, for clinical use,
oral or nasal administration of microparticles may be more
acceptable. For oral administration additional encapsulation
to allow passage through the acidic environment of the
stomach would be necessary. Delivery of DNA by these
routes is likely to be relatively inefficient compared to the
use of specific vectors. For example, we have recently
demonstrated that oral dosing of mice with replication-
deficient recombinant adenovirus expressing the measles
virus nucleocapsid protein was much more efficient than
oral administration of PLGA microencapsulated plasmid
DNA encoding the same antigen (Fooks et al., 2000; Sharpe
et al., 2002). Nonetheless, the advantages of avoiding an
antivector immune response may outweigh the increased
efficiency of vector delivery. Having demonstrated, in this
pilot study, the feasibility of priming a CTL response by
mucosal delivery of DNA in primates, it will now be im-
portant to define the optimal combination of mucosal and
systemic delivery modalities to elicit protective immune
responses.
Materials and methods
Plasmid DNA and microencapsulation
The plasmid, designated pTH.HW, encoding multiple
HIV-1 CTL epitopes and several SIV epitopes together with
the SV5 Pk tag epitope was essentially as described by
Hanke et al. (1998), but the Mamu-A*01-restricted SIV Gag
epitope encoding sequence was modified to encode the
optimal epitope Gag181–189 as described by Allen et al.
(1998). The plasmid was prepared using standard methods
and purified to be pyrogen-free using the EndoFree Plasmid
Maxi Kit (Qiagen).
DNA was microencapsulated in PLGA as has been de-
scribed previously (Tinsley-Bown et al., 2000). Briefly, a
solution of two PLGA polymers RG502 and RG503 (Boehr-
inger Ingleheim, Germany) were mixed 50:50 in ethyl ac-
etate (4 ml) and emulsified with 0.4 ml of a 10 mg/ml
solution pTH.HW in STE buffer (100 mM NaCl, 10 mM
Tris–HCl, 1 mM EDTA pH 8.0) using a Waring blender
(PGC, USA) set to low power (18,000 rpm). Four 15s
on-cycles punctuated with 15s rest periods were used to
facilitate emulsification. This emulsion was added immedi-
ately to an 8% aqueous polyvinyl alcohol solution (66 ml)
preheated to 30°C and emulsified using the low power
setting of the blender. Again a schedule of 15s on-cycles
punctuated with a 15s rest period was used. The resting
double emulsion was dispersed rapidly in distilled water,
preheated to 37°C with stirring, and stirred at room temper-
ature for 1 h. The microparticles were recovered by centrif-
ugation (18,000 g for 25 min), washed four times with
distilled water, and lyophilized. Particles were stored at
20°C with desiccant prior to use.
Size distribution analysis over a 1 to 30-m range was
carried out using a Microbial Systems Cellfacts analyzer
fitted with a 60-m orifice. The structure of the micropar-
ticles was analyzed by scanning electron microscopy
(SEM). The external structure of the freeze-dried particles
was determined by gently applying the microparticles to
adhesive carbon tabs mounted on SEM specimen stubs. The
specimen stubs were coated with approximately 5 nm gold
by ion beam evaporation prior to examination in a Philips
XL30FEG scanning electron microscope operated at 2 kV
accelerating voltage.
To determine the quantity of plasmid DNA incorporated
into PLGA microparticles, aliquots (10–15 mg) were vor-
texed with 200 mM NaOH in a 1 ml volume and incubated
at 120°C for 10 min. The aqueous phase was recovered by
centrifugation at 8500 g for 10 min in a microcentrifuge and
the DNA concentration was determined by UV absorption
at 260 nm against 200 mM NaOH.
Plasmid DNA was extracted for biophysical analysis by
vortexing aliquots of microparticles (20 mg) with chloro-
form (0.5 ml) and incubating at room temperature for 30
min. STE buffer (1 ml) was added and the mixture was
vortexed to facilitate phase separation. The mixture was
centrifuged for 10 min at 8500 g in a microcentrifuge and
the aqueous phase containing the DNA was removed. The
concentration of DNA was determined by UV spectroscopy.
The recovered DNA was analyzed by electrophoresis of 0.1
g aliquots on 0.8% agarose in TBE gels. Adequate sepa-
ration of the bands for supercoiled, open circular, and linear
DNA was obtained by running the gel for 1 h at 100 V, 400
mA.
Biological activity of recovered DNA was assayed by
transfection of 293 cells. Monolayers (80% confluent) of
293 cells in 6-cm2 dishes were transfected with recovered
DNA using the Effectine Transfection reagent (Qiagen).
One hundred and fifty microliters of EC buffer was added to
1 g of recovered DNA. Eight microliters of enhancer was
added and incubated for 5 min at room temperature. Fol-
lowing centrifugation (10 s, microcentrifuge), 25 l of Ef-
fectine reagent was added and mixed by pipetting five times.
One milliliter of warm growth medium (Dulbecco’s MEM
 10% FCS) was added to the transfection mix and the
mixture was added dropwise, immediately to a washed
monolayer of 293 cells in 4 ml of growth medium. Mono-
layers were incubated at 37°C in a mixture of 5% CO2 
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95% air for 12 h. Expression from the transfected DNA was
detected by immunostaining using a mouse anti-Pk-tag
monoclonal antibody (Serotec). After washing to remove
residual serum and debris, monolayers were fixed with 4 ml
cold methanol for 10 min. After further washing, cells were
blocked with phosphate-buffered saline (PBS) containing
10% FCS for 60 min and then stained with monoclonal
antibody diluted 1/2000 in blocking buffer. After 60 min
monolayers were washed and bound antibody was detected
by reaction with rabbit anti-mouse immunoglobulin–horse-
radish peroxidase (HRP) conjugate (Dako) diluted 1/2000.
After a further 60 min monolayers were washed extensively
in PBS and HRP-labeled cells were detected by reaction
with H2O2 and AEC.
Expression in vitro directly from phagocytosed micro-
particles was investigated on monolayers of RAW 264.7
cells (European Collection of Animal Cell Cultures No.
91062702). Multichamber microscope slides were seeded
with cell suspensions in DMEM containing 10% FCS 0.1
mg/ml kanamycin to give approximately 80% confluency
after overnight incubation. Microparticles suspended in
DMEM  0.1 mg/ml kanamycin were added to wells to
give a range of DNA concentrations between 5 and 20 g
DNA per well. Negative control wells were left untreated.
After 3 h at 37°C, cell sheets were washed three times with
PBS to remove excess microparticles and fresh growth
medium was added. Following incubation for 72 h, cell
monolayers were washed once in PBS and fixed using 0.5%
paraformaldehyde for 10 min at room temperature. Cells
were permeabilized by treatment with 50% ethanol for 5
min, then 70% ethanol for 10 min, followed by 50% ethanol
for 3 min. After washing three times with PBS, nonspecific
reactive sites were blocked by incubation with 2% FCS in
PBS for 1 h at 4°C. Fixed, permeabilized cells were then
incubated overnight at 4°C with 1/100 dilution of mouse
monoclonal antibody anti-SV5 Pk tag (Serotec). Bound
antibody was detected after a further wash in PBS by incu-
bation for 1 h at room temperature with 1/100 dilution of
FITC-conjugated goat F(ab)2 anti-mouse lg (Sigma).
Washed cells were viewed using a UV microscope.
Animals and immunization
Rhesus macaques used in this study were bred within the
United Kingdom and housed according to the Home Office
Code of Practice (1989). Animals were anesthetized by
intramuscular injection with ketamine hydrochloride (Veta-
lar, Park Davis Pontypool, UK) for all procedures requiring
removal from their cages including femoral venipuncture
and immunization. Animals with the Mamu-A*01 tissue
type were selected for this study by sequence-specific
primer (SSP)-PCR and direct sequencing (Knapp et al.,
1997).
Macaques were immunized with 3 ml doses of PLGA
microparticles delivered to the rectal mucosa without
trauma using a soft polypropylene 6FG urinary catheter that
was inserted approximately 8 cm. Subsequently, animals
were immunized by intradermal injection of 5  108 plaque
forming units (PFU) of MVA.HW expressing the HIV-1
multiepitope in 300 l sterile PBS in multiple sites in the
thigh.
CTL assay
PBMC were isolated by Ficoll–Paque (Pharmacia, Mil-
ton Keynes, UK) density centrifugation from heparinized
blood and washed in medium consisting of RPMI 1640
(Gibco, Paisley, UK) supplemented with L-glutamine (2
mM) (Gibco), penicillin (50 U/ml)/streptomycin (50 g/ml)
(Gibco), and 10% heat-inactivated fetal bovine serum
(Flow, Oxon, UK). Splenic mononuclear cells (MNC) and
lymph node MNC were obtained by teasing these tissues
and washing cells in culture medium. Splenic MNC were
purified on Ficoll–Paque cushions. Intraepithelial lympho-
cytes and lamina propria lymphocytes were obtained from
jejunum by mechanical and enzymatic dissociation as de-
scribed previously (Polyanskaya et al., 2001). Cells were
cultured in RPMI 1640 supplemented with L-glutamine (2
mM), penicillin (50 U/ml)/streptomycin (50 g/ml), 2-mer-
captoethanol (0.05 mM), HEPES buffer (25 M), and 10%
heat-inactivated fetal bovine serum containing Gag181–189
peptide at 20 g/ml. Lymphocult T was added to a final
concentration of 10 IU/ml on days 3 and 7. Precursor CTL
were restimulated in vitro on day 7 by the addition of
mitomycin C (25 g/ml, 1 h)-inactivated, peptide-pulsed
autologous B-lymphoblastoid cells (B-LCL). At day 13,
effector cells were washed three times and used in triplicate
at various effector-to-target ratios in a standard chromium
release assay. Autologous B-LCL targets were pulsed with
Gag181–189 peptide and labeled with 150 Ci 51Cr for 2 h.
After washing three times, 5000 cells were added to each
test well. Chromium release was determined in the super-
natants after 4 h. Spontaneous release and total release were
determined from wells containing target cells and medium
alone or with 5% Triton X-100. Responses were considered
positive if there was at least 10% specific lysis above that
obtained from control targets. Spontaneous release from
target cells was less than 18%.
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